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Abstract
Background: Leptomeningeal carcinomatosis (LMC) is frequently associated with hydrocephalus, which quickly
devastates the performance of the patient. Cerebrospinal fluid (CSF) shunt is a widely accepted treatment of choice,
but the clinical outcomes in patients with LMC are not well studied. This study aimed to examine the efficacy of a
CSF shunt in patients with LMC.
Methods: Seventy patients with LMC confirmed by cytology or magnetic resonance imaging (MRI) underwent
ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery. We retrospectively analyzed the clinical
characteristics of patients, symptom improvement after the shunt, rate of complications associated with the surgery,
and overall survival.
Results: Fifty-five patients had systemic cancer as a preceding disease, including lung cancer (45), breast cancer (6),
and others (4). Primary brain tumors were mainly glioma (7) and medulloblastoma (5). Fifty-one patients had VP
shunt, and 19 had LP shunt. After surgery, preoperative symptoms “improved” in 35 patients (50%) and were
“normalized” in 24 of those patients (34%). Shunt malfunction occurred in eight patients, and infection occurred in
eight patients. Seventeen patients underwent revision due to infection, shunt malfunction, or over-drainage. There
were no complications associated with peritoneal seeding during a median follow-up of 3.3 months after surgery.
The median overall survival was 8.7 months (95% confidence interval, 6.0–11.4) from LMC diagnosis and 4.1 months
from shunt surgery.
Conclusion: VP or LP shunt is effective for patients with hydrocephalus from LMC in terms of symptom
improvement and prolonging of overall survival with an acceptable rate of procedure-related complications.
Trial registration: This study was approved by the Institutional Review Board (IRB) of the National Cancer Center
(retrospectively registered, NCC2018-0051).
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Background
Leptomeningeal carcinomatosis (LMC), a terminal disease
defined by spreading of cancer cells in the cerebrospinal
fluid (CSF), affects 5–10% of patients with solid tumors,
and the most notorious of which are melanoma; breast,
lung, and ovarian cancers; and primary brain tumors [1].
LMC has a poor prognosis as the life expectancy after
diagnosis is 4–6 weeks without treatment [1, 2]. LMC is
challenging to treat in many ways. Radiation to local
field has a limited role, as the disease is disseminated
along the neuraxis [3]. Systemic chemotherapy is inef-
fective because of the blood-brain barrier [4]. Intra-CSF
chemotherapy, administered either intrathecally or intra-
ventricularly, can maintain therapeutic drug concentra-
tions in the CSF for 48–72 h [5]; however, a marginal
survival benefit of 3–6 months and suspicious neurotox-
icity raise questions about its effectiveness [6–8].
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Infiltration of the CSF space by cancer cells may ob-
struct CSF pathways and cause CSF malabsorption,
resulting in increased intracranial pressure (ICP) and/or
hydrocephalus [9]. The common presenting symptoms
of LMC include headache, nausea, vomiting, and altered
mentality, all of which are related to increased ICP and
hydrocephalus. Increased ICP causes an uneven distribu-
tion of intrathecally or intraventricularly administered
drugs, making them less effective [10]. Thus, hydroceph-
alus and increased ICP degrade the performance and
prognosis of patients with LMC.
Although CSF shunt surgery is a relatively simple
neurosurgical procedure, the percentage of patients who
receive it is less than the incidence of increased ICP, and
its outcomes are little and rarely reported [11–13]. As
the prognoses of patients with LMC are poor, there is a
tendency for physicians to decline aggressive treatment
such as surgical intervention. Furthermore, complica-
tions such as hemorrhage, infection, and device malfunc-
tion, along with the risk of peritoneal transfer of cancer
cells, are reasons to not perform CSF shunt in patients
with LMC [14, 15].
This retrospective study aimed to evaluate the efficacy
of CSF shunt in patients with LMC in terms of (1)
symptom improvement, (2) malfunction rate, including




This retrospective review was based on the electronic
medical records of 70 consecutive patients that under-
went placement of either ventriculoperitoneal (VP) or
lumboperitoneal (LP) shunt for treatment of increased
ICP or hydrocephalus secondary to LMC between 2002
and 2017 at a single institution, National Cancer Center,
Korea. All patients were diagnosed by CSF cytology and
had a suggestive or definite finding of LMC [16] on
gadolinium-enhanced MRI. This retrospective study was
reviewed and approved by the Institutional Review
Board of the National Cancer Center of Korea
(NCC2018-0043).
Clinical parameters and operative procedures
Demographic data, primary tumor type, preoperative
Karnofsky performance status (KPS) score, and type of
the shunt (VP vs. LP) were analyzed as possible factors
affecting the shunt results. Shunt procedures were per-
formed routinely as described in the literature [13]. The
operating physicians chose the type of shunt and entry
point (in case of VP shunt). The type of reservoir (fixed
vs. programmable) was determined based on the avail-
ability or ICP.
End points
Symptom improvement was evaluated at the time pa-
tients were discharged from the hospital after shunt sur-
gery and defined as follows: (1) “normalized,” all
hydrocephalus-related symptoms were clearly solved; (2)
“improved,” preoperative hydrocephalus-related symp-
toms were improved but remained to some extent; (3)
“not improved,” preoperative hydrocephalus-related
symptoms were unchanged. Complications were classi-
fied as malfunctions or CSF infections that lead to shunt
revision. Causes of malfunctions were confirmed either
by a shunt function test or by intraoperative findings.
Survival time was calculated from either the date of
LMC diagnosis or the day of shunt placement until
death or last follow-up visit.
Statistical analysis
Parameters were analyzed using the Statistical Package
for Social Sciences (SPSS, version 18, Chicago, IL). Cat-
egorical variables were compared between the VP shunt
and LP shunt using the chi-square test. A p < 0.05 indi-
cated statistical significance. A Kaplan-Meier curve was
used to analyze survival rates, and a log-rank test was
used to evaluate prognostic factors associated with OS.
Results
Patient characteristics
Seventy patients (40 females, 30 males) underwent shunt
operation during the study period. All patients had
extraventricular drainage or lumbar drainage to control
increased intracranial pressure or to relieve headache be-
fore the shunt procedure. Disease preceding LMC was
systemic cancer in 55 patients and primary brain tumors
in 15 patients (Table 1). The systemic cancers were
non-small cell lung cancer (NSCLC; n = 45), breast can-
cer (n = 6), leukemia (n = 2), cholangiocarcinoma (n = 1),
and malignancy of unknown origin (n = 1). The primary
brain tumors were high-grade glioma (n = 7), medulloblas-
toma (n = 5), primary neuroectodermal tumor (n = 2), and
atypical teratoid/rhabdoid tumor (n = 1).
The median age of the patients was 53 (range, 1–81)
years. Patients with primary brain tumors had lower me-
dian age than those with systemic cancers (18.0 vs. 56.0
years, p < 0.001). The median preoperative KPS score
was 70 (range, 40–90).
Clinical outcomes after surgery
Fifty-one and 19 patients underwent VP shunt and LP
shunt, respectively. There was no predilection for shunt
type according to preceding disease. Forty-six patients
(92%) with VP shunts and 13 patients (68%) with LP
shunts had a programmable valve [that difference was
because of late availability of programmable valves for
LP shunt (since 2012)].
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After shunt surgery, preoperative symptoms were
“normalized” in 24 patients (34%), “improved” in 35 pa-
tients (50%), and “not improved” in 11 patients (16%).
The type of shunt used (VP vs. LP), preceding disease
(systemic metastases vs. primary brain tumor), and pre-
operative KPS score (≥ 70 vs. < 70) did not affect the
clinical outcomes.
Complications related to the shunt procedure
Median follow-up time was 3.3 (range, 0.2–43.0; 95%
confidence interval, 3.47–6.93) months after the shunt.
Neither peritoneal seeding nor secondary ascites were
observed in all patients during the follow-up period.
Seventeen patients (24%) underwent revision surgery
due to malfunction or infection (eight patients each) or
to intolerable over-drainage symptoms (one patient, case
17, Table 2). The average time between initial surgery
and revision surgery was 1.1 ± 0.86 months. Six patients
required a second revision surgery, and two needed a
third revision.
Infections leading to revision surgery were due to skin
contaminants in six patients, four of which had
Staphylococcus epidermidis infection and a history of
methotrexate intraventricular injection via Ommaya res-
ervoir in the presence of LP shunt (cases 2, 3, 4, and 7).
The other two patients had VP shunts and had Staphylo-
coccus aureus infection at 1 month and 6months after
the shunt surgery, respectively, without any history of
reservoir puncture before the infection (cases 1 and 8).
One patient that was bedridden had a Candida albicans
infection of an abdominal wound 2 weeks after LP shunt
installation (case 6). Another patient had a Klebsiella
pneumoniae infection 4 days after LP shunt installation
(case 5). The infected LP shunts were removed and ei-
ther re-inserted after infection control via the same
route (four patients) or changed to a VP shunt (two pa-
tients). Two patients with VP shunt infection refused to
undergo new shunt insertion.
Shunt malfunction occurred in eight patients. In four
patients, shunt function study documented the malfunc-
tion site. Two patients with VP shunts and glioblastoma
(case 9) and medulloblastoma (case 10) showed distal
and ventricular catheter obstruction, respectively. No
cancer cell obstruction but only myxoid material was
found in the ventricular catheter from the patient with
medulloblastoma. Two patients with LP shunts with fixed
pressure-valve reservoirs had proximal catheter obstruc-
tion (case 14) and distal catheter leakage at the junction
with the reservoir (case 16), respectively. In another two
patients, X-ray examination revealed mechanical failures
due to proximal catheter migration (case 11) and distal
catheter malposition into the pre-peritoneal space (case
13), respectively. The remaining two patients had LP
shunts with fixed pressure-valve reservoirs. Under-drain-
age was suspected in those patients because of deterior-
ation before revision, although neither obstruction nor
malfunction was found during revision surgery. One pa-
tient received a VP replacement shunt (case 12), and the
other received an intraventricular Ommaya (case 15).
Revision surgery was more common in patients with LP
shunts than in those with VP shunts because of the higher
rates of malfunction (5/14 vs. 3/48, p = 0.017) and infec-
tion (2/49 vs. 6/13, p < 0.001) with the LP shunts. Five out
of seven LP shunts with fixed pressure valve reservoirs
malfunctioned, while all 12 LP shunts with programmable
valves did not. A possible reason for the higher incidence
of infection in the patients with LP shunts is that four out
of 11 patients that received Ommaya intraventricular
chemotherapy had S. epidermidis infection.
Five patients had medulloblastoma, and none of them
showed any sign of peritoneal seeding during 2.9–40.3
months of follow-up.
Overall survival
Fifty-six patients (80%) died during follow-up, 27
(48%) because of LMC progression and 13 (23%)
Table 1 Characteristics of patients with leptomeningeal carcinomatosis (LMC) receiving cerebrospinal fluid (CSF) shunt operation
Characteristics All patients (n = 70) Metastases (n = 55) Primary brain tumors (n = 15) p value
Median age (range) 53.0 (1–81) 56.0 (34–81) 18.0 (1–66) < 0.001
Gender 0.62
Male 30 24 6
Female 40 31 9
Shunt type 0.11
VP 51 38 13
LP 19 17 2
KPS score 0.099
≥ 70 41 35 6
< 70 29 20 9
Abbreviations: KPS Karnofsky performance status, LP lumboperitoneal, VP ventriculoperitoneal
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because of systemic disease progression. The cause of
death was undetermined in 16 patients (29%). The
median survival of all patients was 8.7 months (range,
0.2–52; 95% confidence interval (CI), 6.0–11.4; Fig. 1)
after LMC diagnosis and 3.9 months (95% CI, 2.6–
5.2) after initial shunt surgery.
Patients with LMC from systemic cancer had signifi-
cantly shorter OS than patients with primary brain tu-
mors (7.6 vs. 13.9 months, p = 0.03, Fig. 1b). Patients
with breast cancer had longer OS than patients with
NSCLC (17.2 vs. 7.6 months, p = 0.044).
The OS of patients with LMC from NSCLC (n =
45) was compared to patients from another set of
patients (n = 46) with LMC from NSCLC who had
increased ICP and received intraventricular chemo-
therapy (n = 105) but did not receive shunts in a his-
torical data [17]. The OS of NSCLC patients with
the shunt (7.6 months; 95% CI, 5.8–9.4) was signifi-
cantly prolonged compared to that of NSCLC
patients without the shunt (2.3 months; 95% CI, 1.6–
3.0) (p < 0.001, Fig. 2).
Discussion
Despite the poor prognosis associated with LMC, CSF
shunting to treat hydrocephalus or increased ICP signifi-
cantly attenuated symptoms and prolonged OS in this
study.
Effectiveness of CSF shunt in patients with LMC
Most studies reporting clinical results of CSF shunts in pa-
tients with LMC have focused on the analysis of LMC or
CNS metastases, and few patients with those conditions re-
ceive shunt procedures [11, 18]. Omuro et al. [19] reviewed
the outcomes of 37 patients with LMC from systemic can-
cer (excluding primary brain tumors) that received VP
shunt for increased ICP and reported improvement of
ICP-related symptoms in 27 patients (77%). Lee et al. [13]
reported a similar improvement rate of 80% after VP shunt
in patients with CNS metastases (40 patients with LMC
and 10 patients with parenchymal brain metastases), not-
ing improvement of headache (86% of patients), gait dis-
turbance (71% of patients), cognitive dysfunction (40% of
patients), and urinary incontinence (40% of patients). In
Table 2 Description of shunt revision due to malfunction and infection
Case no. Sex/age Primary ca. Shunt type/reservoir Malfunction or infection Revision
1 M/34 NSCLC VP/programmable S. aureus infection presented as malfunction with
pus discharge around the distal catheter at 1 month
Shunt removal
2 F/61 Breast ca. LP/programmable S. epidermidis infection after Ommaya MTX injection Shunt removal and VP shunt
2 months later
3 F/56 Breast ca. LP/programmable S. epidermidis infection after Ommaya MTX injection Shunt removal, lumbar drainage,
and re-insertion after infection control
4 F/61 NSCLC LP/programmable Wound dehiscence after Ommaya MTX injection
resulted in S. epidermidis infection
Shunt removal, extraventricular drainage,
and re-insertion after infection control
5 F/63 NSCLC LP/programmable K. pneumoniae infection 4 days after the shunt Shunt removal and extraventricular
drainage
6 F/59 NSCLC LP/programmable C. albicans infection of abdominal wound Shunt removal and VP shunt
7 F/18 MBL LP/programmable S. epidermidis infection after Ommaya MTX injection Shunt removal and re-insertion after
infection control
8 F/59 NSCLC VP/programmable S. aureus infection 6 months after the shunt Shunt removal
9 F/29 GBL VP/programmable Distal catheter obstruction 3 months after the shunt Distal catheter externalization




11 M/1 MBL VP/programmable Proximal catheter migration on 10 days after
the shunt
Shunt revision
12 M74 NSCLC LP/fixed Under-drainage without obstruction Catheter irrigation and VP shunt later
13 F/52 NSCLC LP/fixed Distal catheter (pre-peritoneal) malposition Distal wound revision
14 M/52 NSCLC LP/fixed Proximal catheter obstruction LP shunt removal and VP shunt
15 M/54 NSCLC LP/fixed Under-drainage without obstruction LP shunt removal and ventricular
Ommaya
16 M/53 AOG LP/fixed Distal catheter leakage with reservoir LP shunt removal and VP shunt
17 F/8 MBL VP/fixed Intolerable over-drainage Revision with programmable valve
Abbreviations: AOG anaplastic oligodendroglioma, GBL glioblastoma, LP lumboperitoneal, MBL medulloblastoma, MTX methotrexate, NSCLC non-small cell lung
cancer, VP ventriculoperitoneal
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Fig. 1 Overall survival (OS) of patients who received CSF shunts due to hydrocephalus from leptomeningeal carcinomatosis (a). OS according to
preceding disease of brain metastases and primary brain tumors (b) (n = 70)
Fig. 2 Comparison of overall survival time of patients with non-small cell lung cancer that received shunt surgery (n = 45) versus that of patients
with non-small cell lung cancer that did not receive shunt surgery but received conventional intraventricular chemotherapy (n = 101; data
published in J Thorac Oncol, 2013 [17])
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the present study, 59 patients (84%) had improvement of
preoperative symptoms, including 24 patients (34%) whose
condition was “normalized.” Future studies will need to dif-
ferentiate between symptoms caused by hydrocephalus and
those caused by LMC (e.g., altered mentality) or brain tu-
mors, in case of accompanying parenchymal mass lesions.
Despite the improvements in symptoms, some shunt
surgeries resulted in revisions due to malfunction or in-
fection. Complication rates following shunt procedures
vary from 4 to 85% according to the shunt type (VP vs.
LP), procedure (freehand vs. stereotactic), valve type
(programmable vs. fixed), or chronology [20–23]. In a
nation-wide (the USA) study of revision rates after shunt
surgery in 4480 patients with idiopathic intracranial
hypertension from 2005 to 2009, Menger et al. reported
that 3.9% of VP shunts and 7.0% of LP shunts (p < 0.0001)
required revision [15]. The revision rate in patients with
LMC appears to be higher than those figures. In this
study, LP shunts with fixed pressure-valve reservoirs had
the highest revision rate (5 out of 7) among the shunt and
reservoir types; VP shunts malfunctioned in three out of
51 patients (5.9%). Omuro et al., who used only VP shunts
for patients with LMC, reported that 8% of the shunts
malfunctioned and required revision surgery. Neither the
present study nor that of Omuro et al. found cancer cell
obstruction of the shunt tubing or the reservoir. Another
dangerous potential complication of CSF shunts is peri-
toneal seeding of cancer cells. To date, the documented
cases of such seeding are mostly from medulloblastomas,
which are well known to cause extra-neural metastases
[14, 24, 25]. In those cases, the shunt was inserted be-
fore or after tumor removal, and peritoneal seeding oc-
curred with or without primary tumor recurrence.
Although the five patients with medulloblastoma in the
present study had no documented shunt-mediated me-
tastasis, such metastasis has been diagnosed up to 5
years after shunt placement [25].
Overall survival after the shunt
VP shunt has been suggested to relieve increased
ICP and to improve the OS of patients with LMC
[6, 9, 11]. Omuro et al. reported median OS among
37 patients with LMC from systemic cancer as 2
months after the shunt and 4 months after diagnosis
of LMC (range, 2 days to 3.6 years) [19]. Jung et al. re-
ported that patients with LMC and hydrocephalus that re-
ceived surgical treatment had longer OS than those that
did not receive surgical treatment (5.7months vs. 1.7
months), although the difference was not statistically sig-
nificant because of the small numbers of patients (n = 7
and 11, respectively) [11]. In the present study, patients
with LMC from systemic cancer showed a median OS of
7.6 months after diagnosis.
Appropriate shunt types in patients with LMC
Both VP and LP shunting could safely divert CSF flow
either from a ventricle or spinal arachnoid space to peri-
toneal space. Each type of shunt system has advantages
and disadvantages, so the choice should be tailored to
the patient’s condition. In general, LP shunting is con-
fined to communicating hydrocephalus (HCP) and pref-
erentially used in patients who are not suitable for
cranial surgery (i.e., idiopathic intracranial hypertension
with slit ventricle) or who want to avoid cranial surgery,
whereas VP shunting can be used regardless of
communicating or non-communicating HCP [15, 26].
Earlier-era LP shunts without adjustable valve reservoirs
had problems in adjusting the amount of CSF drainage
and assessing the shunt patency [27, 28]. Hence, LP
shunts have been less frequently used than VP shunts.
Those problems are much reduced since the advent of
LP shunts with programmable valve reservoirs [29]. In
the present study, all mechanical malfunctions of LP
shunts occurred with the fixed-valve reservoir type; LP
shunts with programmable valve reservoirs had revisions
due only to infection.
Continuing intraventricular chemotherapy was tried in
patients with LMC and a shunt. For those with VP shunt,
CSF is directly drained into the peritoneal space from the
ventricle, and therefore, a drug delivered intraventricularly
would be mainly carried not into lumbar/cisternal CSF
space but into the peritoneal space. To overcome this prob-
lem, on-off valve system had been tried in other studies for
the purpose of enforcing drug delivery to lumbar/cisternal
CSF space by closing the shunt [30]. However, we still have
not had pharmacokinetic data that showed how much of
the intraventricularly injected drug reached lumbar/cister-
nal CSF space during valve-off time in these patients who
lost their physiologic CSF flow unless they injected the
drug via lumbar puncture. In this study, we used a combin-
ation of Ommaya reservoir and LP shunt. Previously, this
concurrent use of Ommaya reservoir and LP shunt was
studied for the access to CSF space in the era of LP shunt
without reservoir valve system. Zhang et al. reviewed the
LP shunting in patients with LMC and suggested a
hypothetical advantage of cooperative use of Ommaya
reservoirs [31]. Eleven patients in the present study
received an LP shunt in addition to a pre-installed
Ommaya reservoir for the purpose of intraventricular
chemotherapy. We measured lumbar methotrexate
level from LP shunt reservoir in a patient and evalu-
ated therapeutic concentration was achieved at ap-
proximated half-time of 2.3–4.2 h (data not provided).
Four of those patients contracted S. epidermidis infec-
tions after intraventricular chemotherapy injection.
Recent improvements in aseptic techniques of intra-
ventricular chemotherapy injection have so far re-
sulted in no further CSF infections in our institution.
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Conclusion
Patients with LMC and increased ICP or hydrocephalus
benefit from CSF shunt in terms of symptom alleviation
and survival. Although shunt malfunctions and
infections may occur, careful aseptic technique and so-
phisticated programmable valve systems decrease the
procedure-related complications.
Abbreviations
CSF: Cerebrospinal fluid; HCP: Hydrocephalus; ICP: Intracranial pressure;
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